Last edition
News about "AusperBio "
AusperBio Doses First Patient in HBV Candidate AHB-171 Study
AusperBio has dosed the first patient in the AHB-171 clinical study, advancing its HBV pipeline and proprietary Au-HALO liver-targeting delivery technology siRNA platform.
AusperBio | 03/08/2026 | By News Bureau | 134
AusperBio Bags USD 73 Million in Series B Financing for Chronic Hepatitis B
This financing followed the company's Series A round completed in July this year, demonstrating continued investor confidence in its proprietary platform and strategic direction.
AusperBio | 27/12/2024 | By Aishwarya | 258
AusperBio Gets BTD for AHB-137 in Chronic Hepatitis B Treatment
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. have announced that their investigational drug AHB-137 has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
AusperBio | 11/07/2024 | By Aishwarya | 1005
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy